BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Desombere I, Mesalam AA, Urbanowicz RA, Van Houtte F, Verhoye L, Keck ZY, Farhoudi A, Vercauteren K, Weening KE, Baumert TF, Patel AH, Foung SKH, Ball J, Leroux-Roels G, Meuleman P. A novel neutralizing human monoclonal antibody broadly abrogates hepatitis C virus infection in vitro and in vivo. Antiviral Res 2017;148:53-64. [PMID: 29074219 DOI: 10.1016/j.antiviral.2017.10.015] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
Number Citing Articles
1 Echeverría N, Comas V, Aldunate F, Perbolianachis P, Moreno P, Cristina J. In the era of rapid mRNA-based vaccines: Why is there no effective hepatitis C virus vaccine yet? . World J Hepatol 2021; 13(10): 1234-1268 [PMID: 34786164 DOI: 10.4254/wjh.v13.i10.1234] [Reference Citation Analysis]
2 Velázquez-Moctezuma R, Augestad EH, Castelli M, Holmboe Olesen C, Clementi N, Clementi M, Mancini N, Prentoe J. Mechanisms of Hepatitis C Virus Escape from Vaccine-Relevant Neutralizing Antibodies. Vaccines (Basel) 2021;9:291. [PMID: 33804732 DOI: 10.3390/vaccines9030291] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Sayed IM, Meuleman P. Updates in Hepatitis E virus (HEV) field; lessons learned from human liver chimeric mice. Rev Med Virol 2020;30:e2086. [PMID: 31835277 DOI: 10.1002/rmv.2086] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
4 Mesalam AA. Hepatitis C Virus Vaccine Development: A Step Forward. J Infect Dis 2021;223:2014-6. [PMID: 33038255 DOI: 10.1093/infdis/jiaa644] [Reference Citation Analysis]
5 Center RJ, Boo I, Phu L, McGregor J, Poumbourios P, Drummer HE. Enhancing the antigenicity and immunogenicity of monomeric forms of hepatitis C virus E2 for use as a preventive vaccine. J Biol Chem 2020;295:7179-92. [PMID: 32299914 DOI: 10.1074/jbc.RA120.013015] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
6 Burm R, Collignon L, Mesalam AA, Meuleman P. Animal Models to Study Hepatitis C Virus Infection. Front Immunol 2018;9:1032. [PMID: 29867998 DOI: 10.3389/fimmu.2018.01032] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
7 Yato K, Matsuda M, Watanabe N, Watashi K, Aizaki H, Kato T, Tamura K, Wakita T, Muramatsu M, Suzuki R. Induction of neutralizing antibodies against hepatitis C virus by a subviral particle-based DNA vaccine. Antiviral Research 2022. [DOI: 10.1016/j.antiviral.2022.105266] [Reference Citation Analysis]
8 Law M. Antibody Responses in Hepatitis C Infection. Cold Spring Harb Perspect Med 2021;11:a036962. [PMID: 32341067 DOI: 10.1101/cshperspect.a036962] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
9 Mailly L, Wrensch F, Heydmann L, Fauvelle C, Brignon N, Zeisel MB, Pessaux P, Keck ZY, Schuster C, Fuerst TR, Foung SKH, Baumert TF. In vivo combination of human anti-envelope glycoprotein E2 and -Claudin-1 monoclonal antibodies for prevention of hepatitis C virus infection. Antiviral Res 2019;162:136-41. [PMID: 30599173 DOI: 10.1016/j.antiviral.2018.12.018] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
10 Kamath K, Reifert J, Johnston T, Gable C, Pantazes RJ, Rivera HN, McAuliffe I, Handali S, Daugherty PS. Antibody epitope repertoire analysis enables rapid antigen discovery and multiplex serology. Sci Rep 2020;10:5294. [PMID: 32210339 DOI: 10.1038/s41598-020-62256-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
11 Ramirez S, Bukh J. Current status and future development of infectious cell-culture models for the major genotypes of hepatitis C virus: Essential tools in testing of antivirals and emerging vaccine strategies. Antiviral Res 2018;158:264-87. [PMID: 30059723 DOI: 10.1016/j.antiviral.2018.07.014] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]